XRAY•November 16, 2026 at 10:45 PM UTCHealth Care Equipment & Services

Dentsply Sirona Cuts FY26 Sales Guidance to ~$3.5B; Wellspect Growth Offers Limited Offset

Read source article

What happened

Dentsply Sirona reduced its full-year 2026 sales guidance to approximately $3.5 billion, down from the prior range of $3.5 billion to $3.6 billion, reflecting continued softness in its core dental segments. The company's Wellspect Healthcare business grew 10% year over year to $92 million, but that is a small segment and cannot compensate for declines in Connected Technology Solutions, Essential Dental Solutions, and Orthodontic and Implant Solutions. In Q2 2026, CTS constant-currency revenue fell 3.8%, EDS fell 5.0%, and OIS fell 14.9%, indicating that the distributor expansion has not yet translated into higher sell-in. Management's decision to lower guidance suggests that the anticipated second-half recovery is not materializing as quickly as hoped, and that EMEA destocking and digital pricing pressure remain stubborn headwinds. The market should treat this as a confirmation that the turnaround remains unproven, not as a reason to buy on the dip.

Implication

The reduction in full-year sales guidance to about $3.5 billion indicates that management no longer expects to hit the upper end of its previous range, which will likely pressure sentiment and analyst estimates. Wellspect's 10% growth is a positive but tiny segment, and its contribution is not enough to offset the declines in the much larger dental businesses. The key metrics to watch in upcoming quarters are CTS constant-currency growth, which must turn positive after the recent distributor additions in Atlanta and Canada, and gross margin excluding tariff refunds, which needs to show restructuring savings are flowing through. Until those data points improve, the stock is likely to remain range-bound or drift lower, given elevated short interest and a balance sheet with significant net debt. For long-term investors, waiting for entry near the $10 level or for clear evidence of a turnaround is more prudent than buying at current prices, which already embed some recovery expectations.

Thesis delta

The guidance reduction modestly reinforces the WAIT rating but does not break the core thesis. The well-publicized distributor expansion has not yet produced positive CTS growth, and the lowered sales outlook suggests that second-half improvement may be more muted than initially hoped. We continue to require evidence of positive constant-currency CTS growth and cleaner gross margins before upgrading the stock.

Confidence

High